Main Products / Services / Pipelines & Platforms
Sinew Pharma is focused on the development of the following three assets:
1. Hepatotoxicity-free acetaminophen with the pivotal study completed in which no clinically significant hepatotoxicity was observed among the cohorts of study participants taking 4 to 12 grams per day.
2. A novel analgesic combination with non-hepatotoxic acetaminophen and a non-addictive & no/mild respiratory depression kappa-opioid for severe pain management: (1) The pivotal study has completed enrollment of patients undergoing knee replacement; (2) It is a safer and more effective alternative to traditional µ-opioids to combat opioid crisis.
3. First-in-class NCE with high safety profile for MASH (Metabolic dysfunction–associated steatohepatitis) treatment; tackling multiple pathways impacting its pathogenesis with Phase 2a clinical study completed.
Business Interests
▪ licensing ▪ Co-Development ▪ Strategic Alliance
Contact Info
Chu-Chun (June) Huang
Director of Business Development
+886-2-2788-5365 ext. 531
cchuang@sinewpharma.com